Market Risers: Carnival, Coca Cola HBC AG, Fox Marble Holdings, GlaxoSmithKline

Fox Marble Holdings

The stock price for Carnival with company EPIC: LON:CCL has risen 1.75% or 63 points throughout today’s trading session so far. Buyers have stayed positive during the trading session. Range high for the period so far is 3668 and hitting a low of 3598. Volume total for shares traded during this period was 148,288 while the average shares exchanged is 670,384. The stock 52 week high is 4448 which is 850 points difference from the previous days close and putting the 52 week low at 3037 a difference of some 561 points. Carnival now has a 20 SMA at 3589.5 with a 50 day moving average now of 3380.94. This puts the market cap at £26,403.64m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Carnival being recorded at Wednesday, January 15, 2020 at 11:44:02 AM GMT with the stock price trading at 3661 GBX.

The share price for Coca Cola HBC AG found using EPIC: LON:CCH has gained 1.81% or 49 points throughout today’s trading session so far. Investors are a positive bunch during the trading session. The periods high has already touched 2763 meanwhile the session low reached 2677. Volume total for shares traded during this period was 203,968 while the daily average number of shares exchanged is 823,864. The 52 week high for the share price is 3094.45 about 383.45 points difference from the previous close and the 52 week low at 2296 is a variance of 415 points. Coca Cola HBC AG now has a 20 simple moving average of 2623.18 and the 50 day simple moving average now at 2550.13. Market capitalisation for the company is £10,026.31m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Coca Cola HBC AG being recorded at Wednesday, January 15, 2020 at 11:44:00 AM GMT with the stock price trading at 2760 GBX.

The trading price for Fox Marble Holdings EPIC code: LON:FOX has increased 4.17% or 0.1 points throughout the session so far. Traders seem confident during this period. The period high has peaked at 2.5 and a low of 2.41. The total volume of shares exchanged through this period comes to 202,500 with the daily average traded share volume around 397,467. The 52 week high price for the shares is 9.49 some 7.09 points difference from the previous days close and the 52 week low at 1.85 a difference of some 0.55 points. Fox Marble Holdings now has a 20 SMA at 2.53 and now a 50 day moving average at 2.95. The current market cap is £6.57m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Fox Marble Holdings being recorded at Wednesday, January 15, 2020 at 9:43:07 AM GMT with the stock price trading at 2.5 GBX.

The trading price for GlaxoSmithKline with EPIC code: LON:GSK has moved up 1.02% or 18.4 points during the course of today’s session so far. Buyers are a positive bunch during the session. The high for the period has reached 1823.1 dropping as low as 1805.23. Volume total for shares traded at this point reached 1,236,585 with the daily average number around 8,613,096. The stock 52 week high is 1850.4 equating to 46 points difference from the previous days close and putting the 52 week low at 1429.8 making a difference of 374.6 points. GlaxoSmithKline now has a 20 simple moving average of 1805.64 and now its 50 day simple moving average now of 1765.05. The market capitalisation is now £90,938.27m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline being recorded at Wednesday, January 15, 2020 at 11:44:01 AM GMT with the stock price trading at 1822.8 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

    GSK Plc 5-in-1 meningococcal vaccine approved by FDA

    GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.

    Coca-Cola HBC reports strong organic revenue growth of 13.8%

    Coca-Cola HBC AG (LON:CCH) reports a robust 13.8% organic revenue growth in 2024, driven by strategic priorities and expansion across core categories.

    GSK Plc reports strong growth in Specialty Medicines and R&D progress

    GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.

    GSK plc Depemokimab applications accepted for review in China and Japan

    GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.

    GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

    GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.

    GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

    GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates.

      Search

      Search